I am excited to announce Dr. Bishoy M. Faltas has been named Chief Research Officer of the Englander Institute for Precision Medicine (EIPM), effective immediately.
In this new capacity, Dr. Faltas will oversee EIPM's strategic research directions, and develop new programs and partnerships that integrate biology, technology, and clinical advances to revolutionize patient care. Previously serving as the Director of Bladder Cancer Research for EIPM, Dr. Faltas will continue his duties in this role in addition to his new responsibilities as Chief Research Officer. Dr. Faltas’s responsibilities will include leading new faculty recruitment efforts in the basic and translational sciences at EIPM.
Bishoy M. Faltas is the Gellert Family-John P. Leonard, M.D. Research Scholar in Hematology and Medical Oncology and Associate Professor of medicine and of cell and developmental biology. He is an internationally recognized physician-scientist who significantly advanced our understanding of the molecular biology of bladder cancer. He is a practicing oncologist who treats patients with bladder cancer at NewYork-Presbyterian/Weill Cornell Medical Center.
The Faltas Laboratory is dedicated to studying bladder cancer as a model disease for dissecting the fundamental biological mechanisms that drive the evolution of human cancers. Dr. Faltas has published several peer-reviewed publications in high-impact journals, including Nature Genetics and Nature Communications, and has received several awards, including the ASCO Young Investigator Award, the AACR NextGen Star Award, and the ASCI-YPSA Young Investigator Award. He received the NCI R37 MERIT award and funding from the Department of Defense and the STARR Cancer Consortium.
Dr. Faltas's leadership as Chief Research Officer marks an exciting new chapter for EIPM. His pioneering work and visionary and collaborative approach to precision medicine are exactly what we need to drive our mission forward. I am confident that Bishoy's guidance will greatly enhance our research impact and patient care innovations. We are thrilled to have him in this new position.
This appointment comes at a time when EIPM is poised for groundbreaking advancements in genomic medicine and precision health. Our growth has been bolstered recently by a transformation institutional gift from Israel Englander and plans to open new medical research space at 1334 York Avenue.
“I am excited to take on this role at the EIPM at such a transformative moment,” said Dr. Faltas. “It is an exciting time in biomedical research and at EIPM. We are now at a point where we can fuse biological insights, clinical advances, and technology to begin to achieve true precision medicine. The potential to impact patient care positively through precision medicine and artificial intelligence is immense. I am looking forward to building new collaborations with our partners to move the needle on what is possible in biomedical research and patient care at Weill Cornell Medicine.”
Sincerely,
Olivier Elemento, Ph.D.
Director of the Englander Institute for Precision Medicine